Press Releases

HOUSTON, Nov. 12, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the third quarter ended September 30, 2019. Additionally

WASHINGTON, Nov. 12, 2019 /PRNewswire/ -- Thousands of advocates for children's health will gather Thursday at the Vaccine Injury Epidemic (VIE) Event on the National Mall to

YORK, England, Nov. 12, 2019 /PRNewswire/ -- A select group of farmers have pioneered production of Ahiflower — the best plant-derived source of healthy omegas in over 50 years. Omegas are essential for every cell in our bodies — especially joints, brain, heart, and immune system. Humans must obtain them from their di

MINNEAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Representatives from Revel, the nation's leading health action platform, announced today they have broken new ground with a tool that helps identify and prioritize the most effective social determinants of health (SDoH) programs. Revel's Social Determinants of Health Assessment is an advanced, multi-channel outreach program

SEATTLE, Nov. 12, 2019 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that their development and manufacturing capabilities at their Seattle, Washington and Copenhagen, Denmark facilities will be expanded, as part of an

FRANKLIN LAKES, N.J., Nov. 12, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for an expanded version of its BD Onclarity™ HPV Assay.

INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) presented detailed results today demonstrating Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a 52-week placebo-controlled Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of non-radiographic axial spondyloar

NEW YORK, Nov. 12, 2019 /PRNewswire/ -- The FAIR Health Board of Directors has elected Zachary W. Carter to return to his position on the Board, which he left five years ago to serve as Corporation Counsel of the City of New York. A national, independent nonprofit organization dedicated to bringing tran

LOS ANGELES, Nov. 12, 2019 /PRNewswire/ -- Leading the market in mobile medical vehicles, Winnebago Industries, Inc

SAN FRANCISCO, Nov. 12, 2019 /PRNewswire/ -- Doximity today announced its inclusion in